Holley Reports Strong Q4 2025 Financial Results with Significant Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy HLLY?
Source: Newsfilter
- Significant Sales Growth: Holley achieved net sales of $155.4 million in Q4 2025, reflecting a 10.9% year-over-year increase, indicating strong demand in the automotive aftermarket and positioning the company for continued growth in 2026.
- Net Income Turnaround: The company reported a net income of $6.3 million in Q4, a substantial recovery from a net loss of $37.8 million in the same quarter last year, marking a significant improvement in financial health and boosting investor confidence.
- Adjusted EBITDA Increase: Adjusted EBITDA rose to $33.2 million, up 14.1% year-over-year, showcasing Holley's success in operational efficiency and cost management, which further solidifies its market position.
- Free Cash Flow Growth: Holley generated $34.2 million in free cash flow for the full year 2025, despite a decrease from the previous year, demonstrating strong cash generation capabilities that provide funding for future investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HLLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HLLY
Wall Street analysts forecast HLLY stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.020
Low
4.50
Averages
5.25
High
7.00
Current: 4.020
Low
4.50
Averages
5.25
High
7.00
About HLLY
Holley, Inc. is engaged in the design, manufacturing and marketing of high-performance products for automotive enthusiasts. The Company owns and manages a portfolio of brands, catering to a diverse community of enthusiasts passionate about the customization and performance of their vehicles. It is a manufacturer of a diversified line of performance automotive products, including carburetors, fuel pumps, fuel injection systems, nitrous oxide injection systems, superchargers, exhaust headers, mufflers, distributors, ignition components, engine tuners and automotive performance plumbing products. It is also a manufacturer of exhaust products as well as shifters, converters, transmission kits, transmissions, tuners and automotive software. The Company’s products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. Its brands include Holley EFI, Holley, MSD, Simpson, and Flowmaster, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Holleypress Reports Q4 2025 Earnings with Mixed Results
- Earnings Performance: Holleypress reported a Q4 2025 non-GAAP EPS of $0.04, missing expectations by $0.04, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The fourth-quarter revenue reached $155.44 million, reflecting an 11.0% year-over-year increase and exceeding market expectations by $12.69 million, suggesting strong performance in core business despite overall earnings falling short.
- Core Business Sales: Excluding approximately $3.2 million in non-core sales from Q4 2024, core business net sales grew by 13.5% year-over-year, highlighting the company's sustained growth potential in its core market, which is crucial for future strategic planning.
- 2026 Outlook: The company projects full-year 2026 net sales between $625 million and $655 million, with adjusted EBITDA expected to be between $127 million and $137 million, indicating confidence in future growth while also needing to manage capital expenditures and interest expenses carefully.
See More
Holley Reports Strong Q4 2025 Financial Results with Significant Growth
- Significant Sales Growth: Holley achieved net sales of $155.4 million in Q4 2025, reflecting a 10.9% year-over-year increase, indicating strong demand in the automotive aftermarket and positioning the company for continued growth in 2026.
- Net Income Turnaround: The company reported a net income of $6.3 million in Q4, a substantial recovery from a net loss of $37.8 million in the same quarter last year, marking a significant improvement in financial health and boosting investor confidence.
- Adjusted EBITDA Increase: Adjusted EBITDA rose to $33.2 million, up 14.1% year-over-year, showcasing Holley's success in operational efficiency and cost management, which further solidifies its market position.
- Free Cash Flow Growth: Holley generated $34.2 million in free cash flow for the full year 2025, despite a decrease from the previous year, demonstrating strong cash generation capabilities that provide funding for future investments.
See More
Holley Performance Brands Announces Q4 and Full Year 2025 Financial Results Release Date
- Earnings Call Announcement: Holley Performance Brands has scheduled a conference call on March 4, 2026, at 8:30 AM ET to discuss its Q4 and full year 2025 financial results, demonstrating the company's commitment to transparency and investor communication.
- Financial Results Preview: The earnings report will be released before market open on March 4, 2026, providing investors with critical performance metrics that will help analyze the company's future growth potential.
- Executive Participation: The call will be hosted by Holley's President and CEO Matthew Stevenson and CFO Jesse Weaver, indicating the company's emphasis on financial transparency and investor relations.
- Replay and Archive: For those unable to participate, Holley will offer a telephone replay until March 11, 2026, ensuring all stakeholders have access to important information, thereby enhancing the connection between the company and its investors.
See More
Cytokinetics Faces Shareholder Claims Over Executive Misconduct, Potential for Corporate Reforms
- Shareholder Claims Investigation: Grabar Law Office is investigating whether Cytokinetics' executives breached their fiduciary duties, allowing shareholders who purchased shares before December 27, 2023, to seek corporate reforms and fund recovery.
- FDA Review Delays: Cytokinetics acknowledged in May 2025 that it failed to include a Risk Evaluation and Mitigation Strategy in its New Drug Application, resulting in the FDA extending the review date from September 2025 to December 2025, which negatively impacted the company's reputation and shareholder confidence.
- False Statement Allegations: A federal securities fraud class action alleges that Cytokinetics' executives made misleading statements that caused significant harm to shareholders, potentially affecting the company's future financing capabilities.
- Legal Consequences: Shareholders who purchased shares before December 27, 2023, can seek court-approved incentive awards, highlighting potential flaws in corporate governance and legal risks.
See More
Holley Inc. Faces Shareholder Lawsuit Over Securities Fraud Allegations
- Shareholder Lawsuit Initiated: Current shareholders of Holley Inc. (NYSE: HLLY) can seek corporate reforms and fund returns, indicating significant legal challenges that may impact shareholder confidence and market performance.
- Fraud Allegations Survive: A federal securities fraud class action has survived a motion to dismiss, alleging that Holley executives failed to disclose deteriorating relationships with distributors, which could lead to declining sales and affect future revenues.
- Market Trust Crisis: Holley's excessive focus on its direct-to-consumer channel has damaged relationships with distributors, which are crucial for revenue, potentially resulting in market share loss and diminished competitive standing.
- Consequences of Integration Failure: Holley has failed to effectively integrate its acquisitions, leading to operational inefficiencies and inventory management issues, which exacerbate financial pressures and could hinder the company's long-term strategic growth.
See More
Canaccord Genuity Keeps Buy Rating on Holley and Increases Price Target to $7
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared knowledge and resources.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
See More
Holleypress Reports Q4 2025 Earnings with Mixed Results
- Earnings Performance: Holleypress reported a Q4 2025 non-GAAP EPS of $0.04, missing expectations by $0.04, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The fourth-quarter revenue reached $155.44 million, reflecting an 11.0% year-over-year increase and exceeding market expectations by $12.69 million, suggesting strong performance in core business despite overall earnings falling short.
- Core Business Sales: Excluding approximately $3.2 million in non-core sales from Q4 2024, core business net sales grew by 13.5% year-over-year, highlighting the company's sustained growth potential in its core market, which is crucial for future strategic planning.
- 2026 Outlook: The company projects full-year 2026 net sales between $625 million and $655 million, with adjusted EBITDA expected to be between $127 million and $137 million, indicating confidence in future growth while also needing to manage capital expenditures and interest expenses carefully.
See More
Holley Reports Strong Q4 2025 Financial Results with Significant Growth
- Significant Sales Growth: Holley achieved net sales of $155.4 million in Q4 2025, reflecting a 10.9% year-over-year increase, indicating strong demand in the automotive aftermarket and positioning the company for continued growth in 2026.
- Net Income Turnaround: The company reported a net income of $6.3 million in Q4, a substantial recovery from a net loss of $37.8 million in the same quarter last year, marking a significant improvement in financial health and boosting investor confidence.
- Adjusted EBITDA Increase: Adjusted EBITDA rose to $33.2 million, up 14.1% year-over-year, showcasing Holley's success in operational efficiency and cost management, which further solidifies its market position.
- Free Cash Flow Growth: Holley generated $34.2 million in free cash flow for the full year 2025, despite a decrease from the previous year, demonstrating strong cash generation capabilities that provide funding for future investments.
See More
Holley Performance Brands Announces Q4 and Full Year 2025 Financial Results Release Date
- Earnings Call Announcement: Holley Performance Brands has scheduled a conference call on March 4, 2026, at 8:30 AM ET to discuss its Q4 and full year 2025 financial results, demonstrating the company's commitment to transparency and investor communication.
- Financial Results Preview: The earnings report will be released before market open on March 4, 2026, providing investors with critical performance metrics that will help analyze the company's future growth potential.
- Executive Participation: The call will be hosted by Holley's President and CEO Matthew Stevenson and CFO Jesse Weaver, indicating the company's emphasis on financial transparency and investor relations.
- Replay and Archive: For those unable to participate, Holley will offer a telephone replay until March 11, 2026, ensuring all stakeholders have access to important information, thereby enhancing the connection between the company and its investors.
See More
Cytokinetics Faces Shareholder Claims Over Executive Misconduct, Potential for Corporate Reforms
- Shareholder Claims Investigation: Grabar Law Office is investigating whether Cytokinetics' executives breached their fiduciary duties, allowing shareholders who purchased shares before December 27, 2023, to seek corporate reforms and fund recovery.
- FDA Review Delays: Cytokinetics acknowledged in May 2025 that it failed to include a Risk Evaluation and Mitigation Strategy in its New Drug Application, resulting in the FDA extending the review date from September 2025 to December 2025, which negatively impacted the company's reputation and shareholder confidence.
- False Statement Allegations: A federal securities fraud class action alleges that Cytokinetics' executives made misleading statements that caused significant harm to shareholders, potentially affecting the company's future financing capabilities.
- Legal Consequences: Shareholders who purchased shares before December 27, 2023, can seek court-approved incentive awards, highlighting potential flaws in corporate governance and legal risks.
See More
Holley Inc. Faces Shareholder Lawsuit Over Securities Fraud Allegations
- Shareholder Lawsuit Initiated: Current shareholders of Holley Inc. (NYSE: HLLY) can seek corporate reforms and fund returns, indicating significant legal challenges that may impact shareholder confidence and market performance.
- Fraud Allegations Survive: A federal securities fraud class action has survived a motion to dismiss, alleging that Holley executives failed to disclose deteriorating relationships with distributors, which could lead to declining sales and affect future revenues.
- Market Trust Crisis: Holley's excessive focus on its direct-to-consumer channel has damaged relationships with distributors, which are crucial for revenue, potentially resulting in market share loss and diminished competitive standing.
- Consequences of Integration Failure: Holley has failed to effectively integrate its acquisitions, leading to operational inefficiencies and inventory management issues, which exacerbate financial pressures and could hinder the company's long-term strategic growth.
See More
Canaccord Genuity Keeps Buy Rating on Holley and Increases Price Target to $7
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from shared knowledge and resources.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
See More
